Advanced search
Publication Cover
Canadian Journal of Respiratory, Critical Care, and Sleep Medicine
Revue canadienne des soins respiratoires et critiques et de la médecine du sommeil
Volume 6, 2022 - Issue 5
Submit an article Journal homepage
467
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Trastuzumab-deruxtecan: New treatment, familiar complications

Lee Fidlera Division of Respirology, Department of Medicine, Sunnybrook Health Sciences Center, Toronto, Ontario, CanadaCorrespondence[email protected]
&
Sandeep Sehdevb Division of Medical Oncology, Department of Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada
Pages 281-282 | Published online: 29 Aug 2022

References

  • Umezawa H, Maeda K, Takeuchi T, et al. New antibiotics, bleomycin A and B. J Antibiot. 1966;19(5):200–209.
  • Moeller A, Ask K, Warburton D, et al. A bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40(3):362–382. doi:10.1016/j.biocel.2007.08.011.
  • Watson RA, De La Pena H, Tsakok MT, et al. Development of best-practice guideline for the use of bleomycin in the treatment of germ cell tumours in the UK. Br J Cancer. 2018;119(9):1044–1051. doi:10.1038/s41416-018-0300-x.
  • Skoech S, Weatherley N, Swift AJ, et al. Drug-induced interstitial lung disease: as systematic review. J Clin Med. 2018;7(10):356. doi:10.3390/jcm7100356.
  • Approved in 2020: drugs for human use. https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/drug-medical-device-highlights-2020/approved-2020-drugs-human-use.html#antineoplastic.
  • Breast cancer statistics. https://cancer.ca/en/cancer-information/cancer-types/breast/statistics.
  • Patel A, Unni N, Peng Y. The changing paradigm for the treatment of HER2-positive breast cancer. Cancers. 2020;12(8):2081. doi:10.3390/cancers12082081.
  • Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. NEJM. 2001;344:783–792. doi:10.1056/NEJM200103153441101.
  • Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164–172. doi:10.1016/S0140-6736(13)62422-8.
  • Cortes J, Kim SB, Chung WP, et al. Trastuzumab deruxtecan versus trasuzumab emtansine for breast cancer. NEJM. 2022;386:1143–1154. doi:10.1056/NEJMoa2115022.
  • Denduluri N, Somerfield MR, Chavez-MacGregor M, et al. Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO guideline update. J Clin Oncol. 2021;39(6):685–693. doi:10.1200/JCO.20.02510.
  • Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. NEJM. 2020;382:610–621. doi:10.1056/NEJMoa1914510.
  • Li B, Smit EF, Goto Y, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. NEJM. 2022;386:241–251. doi:10.1056/NEJMoa2112431.
  • Siena S, Di Bartolomeo M, Raghav K, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021;22(6):779–789. doi:10.1016/S1470-2045(21)00086-3.
  • Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. NEJM. 2020;382:2419–2430. doi:10.1056/NEJMoa2004413.
  • Dieas V, Deluche E, Lusque A, et al. Trastuzumab deruxtecan for advanced breast cancer patients, regardless of HER2 status: A phase II study with biomarkers analysis. (DAISY). 2021 San Antonio Breast Cancer Symposium. Abstract PD8-02. doi:10.1158/1538-7445.SABCS21-PD8-02.
  • Abuhelwa Z, Alloghbi A, Alqahtani A, et al. Trastuzumab deruxtecan-induced interstitial lung disease/pneumonitis in ERBB2-positive advanced solid malignancies: a systematic review. Drugs. 2022;82(9):979–987. doi:10.1007/s40265-022-01736-w.
  • Product monograph. Including patient medication information. ENHERTUTM https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/enhertu-product-monograph-en.pdf.
  • Hannen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv264–66. doi:10.1093/annonc/mdy162.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.